SCHEMBL826634

SCHEMBL826634

N#Cc1cc(Cl)c2ccoc2c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.46
XDH P47989 3/20 0.45
SLC22A12 Q96S37 3/20 0.45
GRM5 P41594 1/20 0.38
MAOA P21397 2/20 0.37
MAOB P27338 2/20 0.37
IDO1 P14902 1/20 0.34
FTO Q9C0B1 1/20 0.33
VCAM1 P19320 2/20 0.32
KCNA3 P22001 4/20 0.31
KCNA5 P22460 3/20 0.31
FASN P49327 1/20 0.31
AR P10275 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18585565 0.78 XDH (0.55) CYP2A6XDHSLC22A12GRM5FTO
SCHEMBL1256888 0.74 AHR (0.41) CYP2A6MAOAMAOBFTOKCNA3
SCHEMBL18585772 0.74 KDM4E (0.47) CYP2A6XDHSLC22A12GRM5MAOA
SCHEMBL5780690 0.73 GRM5 (0.64) CYP2A6XDHSLC22A12GRM5MAOA
SCHEMBL30744099 0.73 GRM5 (0.64) CYP2A6XDHSLC22A12GRM5MAOA
SCHEMBL31749636 0.70 CYP2A6 (0.50) CYP2A6XDHSLC22A12GRM5VCAM1
SCHEMBL506960 0.67 CYP2A6 (0.71) CYP2A6XDHSLC22A12MAOAMAOB
SCHEMBL20301257 0.66 MAOA (0.62) CYP2A6GRM5MAOAMAOBFTO
SCHEMBL23087600 0.65 CA1 (0.59) CYP2A6XDHSLC22A12FASNAR
SCHEMBL7931074 0.65 VCAM1 (0.46) MAOAMAOBVCAM1ARALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507680-B2 Production process of a heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2013-08-13 US disclosed
US-20120142924-A1 PRODUCTION PROCESS OF A HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST MITSUBISHI RAYON CO., LTD. (JP) 2012-06-07 US disclosed
US-8143407-B2 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2012-03-27 US disclosed
EP-1481978-B1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST MITSUBISHI RAYON CO (JP) 2011-09-14 EP disclosed
US-20100010224-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST MITSUBISHI RAYON CO., LTD. (JP) 2010-01-14 US disclosed
US-7612218-B2 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2009-11-03 US disclosed
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2005-07-07 US disclosed
EP-1481978-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST Mitsubishi Rayon Co., Ltd. (JP) 2004-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010224-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST PIN4, IPO5, HLCS CYP2A6 405/4885XDH 2526/4885SLC22A12 3600/4885
US-20120142924-A1 PRODUCTION PROCESS OF A HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST PIN4, NISCH, HLCS CYP2A6 560/4885XDH 3129/4885SLC22A12 3585/4885
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst PIN4, IPO5, HLCS CYP2A6 405/4885XDH 2526/4885SLC22A12 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.